INDSWFTLAB

**Growth Outlook & CDMO Expansion** **

:** Guided for **20–25% revenue CAGR**, targeting topline growth from **₹636 crore to ₹1,200+ crore by FY29**. The company expects **₹200–220 crore** incremental FY27 revenue from commercialized CDMO and branded partnerships with **Viatris (Ireland/Europe), Manx (UK) and Arrotex (Australia)**, while planning to file **400+ dossiers by FY27** to strengthen its IP-led product pipeline. **Impact:** **Positive;** strong growth guidance, expanding global CDMO partnerships and a robust dossier pipeline enhance long-term revenue visibility.